Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases.

Publisher:
Ubiquity Press, Ltd.
Publication Type:
Journal Article
Citation:
Global heart, 2020, 15, (1), pp. 57
Issue Date:
2020-08-19
Filename Description Size
860-2579-1-PB.pdfPublished version939.86 kB
Adobe PDF
Full metadata record
Highlights:  - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.- A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.- The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.- Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.- Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.
Please use this identifier to cite or link to this item: